Glycosaminoglycans in Cardiovascular and Kidney Disease Research
Mechanistic evidence, experimental models and clinical translation
Abstract
Glycosaminoglycans (GAGs) are structural and regulatory components of the endothelial surface layer, vascular extracellular matrix and kidney filtration interface. Heparan sulfate, hyaluronan and other GAG chains contribute to hydration, protein recognition, cellular signaling and the organization of tissue barriers. Changes in their abundance, sulfation or turnover have been described in vascular inflammation, metabolic disease and several forms of kidney injury. However, observed changes in GAG-associated markers are not always sufficient to establish cause and effect.
This evidence review examines proposed cardiovascular and renal mechanisms, contrasts findings from genetic and disease models, and evaluates why apparently encouraging laboratory observations do not always translate into reproducible clinical benefit. Particular attention is given to the challenged historical concept that glomerular basement membrane heparan sulfate, by itself, accounts for charge-selective albumin filtration, and to conflicting clinical results for selected GAG-based interventions.
glycosaminoglycans (GAGs), vascular endothelial glycocalyx, glomerular filtration barrier, heparan sulfate proteoglycans, diabetic kidney disease, albuminuria, sulodexide clinical evidence
1. GAG Biology in Cardiovascular and Renal Health
GAGs are negatively charged polysaccharides comprising repeating disaccharide units, with chemical properties governed by uronic-acid composition, N-acetylation, epimerization and variable sulfation. Heparan sulfate (HS) is usually linked to proteoglycan core proteins such as syndecans, glypicans, agrin and perlecan. Hyaluronan (HA) is a nonsulfated GAG that is not covalently attached to a core protein in the same manner. Other chains, including chondroitin sulfate and dermatan sulfate, occur in extracellular matrix and connective tissues.
At the luminal endothelial interface, proteoglycans and associated GAGs contribute to the glycocalyx, an organized but dynamic surface layer interacting with plasma proteins and the surrounding flow environment. Within the kidney, GAG-bearing structures are distributed among glomerular endothelial cells, the glomerular basement membrane (GBM), mesangial matrix and renal interstitium. These compartments have distinct cellular sources and biological roles; detecting HS loss in one does not necessarily identify injury to another.
The functional significance of sulfated GAGs goes beyond their electrostatic properties. Defined motifs can interact with chemokines, growth factors, coagulation-related proteins and complement regulators. The same GAG family may therefore affect vascular inflammation, repair and tissue homeostasis through more than one pathway.
| GAG-associated compartment | Representative constituents | Research focus | Interpretive caution |
|---|---|---|---|
| Vascular endothelial surface | HS, HA, syndecans, glypicans | Permeability, shear responses, leukocyte interactions | Surface coverage varies by vascular bed and preparation |
| Glomerular endothelium | HS- and HA-associated glycocalyx | Albumin passage, vascular injury | Endothelial changes coexist with podocyte and GBM changes |
| Glomerular basement membrane | Agrin-associated HS, basement membrane matrix | Complement regulation and matrix organization | Charge depletion does not reliably cause albuminuria on its own |
| Mesangium and interstitium | Proteoglycans, HA and sulfated GAGs | Matrix remodeling, fibrosis, inflammation | Changes may be secondary to cell activation and injury |
2. Glycocalyx Alterations in Vascular Disease
The endothelial glycocalyx supports interactions between the vessel wall and circulating blood. Experimental models associate its disruption with altered barrier behavior, heightened adhesion of leukocytes and changes in the endothelial response to mechanical forces. Hyperglycemia, reactive oxygen species, ischemia-reperfusion and inflammatory mediators can modify glycocalyx-associated constituents through shedding, altered biosynthesis or enzymatic degradation.
Heparanase cleaves HS chains, whereas hyaluronidases and other remodeling pathways can affect HA-containing structures. Syndecan ectodomain shedding is often assessed using soluble syndecan-1, but soluble markers do not uniquely reflect the amount of glycocalyx still covering the vascular lumen. Systemic concentrations also depend on release from multiple tissues, clearance and sampling time.
2.1 Barrier function and shear sensing
GAG-bearing structures participate in a coupled network involving the endothelial cytoskeleton, junctional proteins and nitric oxide signaling. Loss of surface components may coincide with an increase in tracer permeability or impaired shear-responsive signaling. Nevertheless, glycocalyx removal can have different physiological consequences under static cell culture and sustained flow. A rise in permeability should not be attributed to GAG loss unless tight-junction injury, cytotoxicity and inflammatory pathways have also been assessed.
2.2 Human evidence and its limits
Observational studies report altered glycocalyx-related measurements in populations with diabetes, kidney dysfunction and cardiovascular risk factors. Commonly used metrics include perfused boundary region imaging, circulating shedding products and functional vascular measurements. These methods capture related but nonidentical properties. Cross-sectional associations cannot determine whether glycocalyx injury is an initiating driver of disease, a consequence of inflammation or both.
Figure 1. Conceptual comparison of a relatively preserved endothelial glycocalyx and inflammation-associated surface disruption. Schematic only; not experimental microscopy or a quantitative depiction of layer thickness.
3. GAGs and Glomerular Barrier Function
The glomerular filtration barrier is a coordinated system of fenestrated endothelial cells and their surface layer, the GBM, and podocytes with slit diaphragms. Each component can influence albumin handling. Classical theories assigned substantial charge selectivity to negatively charged HS chains in the GBM; however, genetic studies have significantly revised that interpretation.
Agrin is a major HS proteoglycan of the mature GBM. Experimental deletion of agrin, including combined reduction of agrin and perlecan-associated HS, greatly lowers detectable GBM anionic sites without necessarily producing proteinuria. Such results challenge the premise that loss of GBM negative charge alone is sufficient to cause clinically relevant albumin leakage. They do not establish that HS is biologically dispensable: its functions may include matrix interactions and recognition of complement regulator factor H.
By comparison, the luminal glomerular endothelial surface layer may make a meaningful contribution to albumin restriction and microvascular function. Its role is experimentally difficult to isolate because endothelial perturbations often occur together with podocyte injury, GBM remodeling and systemic hemodynamic changes. It is important to distinguish endothelial glycocalyx from GBM-associated HS in both imaging and mechanistic writing.
Reduced HS staining or a lower GBM negative charge is not, on its own, proof that loss of charge caused proteinuria. Genetic loss-of-function studies show that substantial reductions in GBM anionic sites can coexist with a functioning filtration barrier. Proposed complement-regulatory functions require separate assays.
Figure 2. Major layers of the glomerular filtration barrier. Endothelial surface GAGs and GBM-bound heparan sulfate occupy different anatomical compartments and should be measured separately.
4. GAG-Related Changes in Diabetic Kidney Disease
Diabetic kidney disease develops through intertwined metabolic, vascular, inflammatory and structural processes. Hyperglycemia and metabolic stress can affect endothelial signaling, glomerular permeability, mesangial expansion, podocyte health and extracellular matrix turnover. Studies report changes in renal HS distribution, expression of heparanase and glycocalyx-associated markers in some diabetic models and patient groups. The direction and magnitude of these changes vary with disease stage, tissue compartment and assay.
4.1 Heparanase, HS and inflammatory signaling
Heparanase activity may increase HS cleavage and release fragments capable of participating in local inflammatory and signaling processes. Nevertheless, elevated heparanase expression and altered HS staining do not establish that this pathway alone drives albuminuria. The consequences can depend on the underlying disease model and concurrent injury to the filtration barrier.
4.2 Interpreting albuminuria
Urinary albumin-to-creatinine ratio (UACR) is an important clinical and experimental outcome but is not a direct measurement of glycocalyx restoration. It can change through hemodynamic factors, altered glomerular filtration, tubular albumin handling, systemic blood pressure and other mechanisms. A decrease in albuminuria should therefore be reported as a renal biomarker response, not as direct proof that HS or HA synthesis has normalized.
Likewise, circulating syndecan-1 and HA can reflect multiple vascular or tissue sources, and kidney clearance may affect observed concentrations. Studies that combine structural endothelial imaging, HS disaccharide profiling, UACR, estimated glomerular filtration rate (eGFR) and renal histology provide a more defensible mechanistic interpretation than those relying on a single marker.
5. Experimental Evidence from Preclinical Models
Cellular, genetic and animal systems offer complementary tests of GAG-related mechanisms. Cultured endothelial cells allow tightly controlled exposures to glucose, inflammatory mediators or candidate GAG mixtures, but their glycocalyx may be underdeveloped without physiological flow. Microfluidic models can introduce shear stress and visualize barrier changes, though they do not fully reproduce the immune, metabolic and hemodynamic environment of the whole kidney.
Genetic models that alter HS biosynthesis or specific proteoglycans can establish whether a component is necessary in a given compartment. Their phenotypes also demonstrate why results from enzymatic cleavage, genetic ablation and pharmacologic administration should not be treated as interchangeable. Animal models of diabetic kidney injury can help connect GAG changes to renal physiology, but species differences, disease duration and treatment timing limit direct extrapolation.
| Model or method | Useful outputs | Strength | Main limitation |
|---|---|---|---|
| Static endothelial culture | GAG staining, junction proteins, permeability | Controlled perturbation | Limited physiological surface layer |
| Endothelium under flow | Shear response, adhesion, glycocalyx imaging | Better vascular relevance | Simplified cell interactions |
| HS/proteoglycan genetic models | Barrier phenotype, complement deposition | Tests molecular necessity | Compensation and tissue-specific effects |
| Diabetic rodent kidney models | UACR, renal histology, GAG distribution | Organ-level assessment | Differences from human DKD |
| Human samples and biopsies | HS localization, markers, pathology correlation | Clinical disease context | Often observational and cross-sectional |
Appropriate controls include untreated and vehicle-exposed groups, matched glucose/osmolarity controls when relevant, molecular-weight- and charge-matched comparator polysaccharides, and an independent measure of cell viability. For GAG-based research materials, lot characterization, source and dose should be explicit. This is particularly important for heterogeneous mixtures such as sulodexide because two preparations may have similar labels but different chain-size or sulfation distributions.
6. Clinical Research on Selected GAG-Based Interventions
Human evidence must be separated by indication, intervention, population and endpoint. Some studies have explored oral or parenteral sulodexide, a mixture of heparin-related and dermatan sulfate fractions, for diabetes-associated albuminuria and vascular conditions. Earlier small studies sometimes reported reductions in albumin excretion, which prompted larger trials. Those confirmatory trials did not reproduce a clinically meaningful renal benefit in the populations tested.
6.1 Contrasting sulodexide trials
The Di.N.A.S. randomized study of 223 participants with type 1 or type 2 diabetes reported a dose-related albuminuria reduction during sulodexide treatment. In contrast, the larger randomized Sun-MICRO trial enrolled 1,056 patients with type 2 diabetes and microalbuminuria already treated with renin-angiotensin system blockade and found no improvement in the prespecified albuminuria response versus placebo. The Sun-MACRO trial enrolled 1,248 patients with overt diabetic nephropathy and renal impairment; it was terminated early after interim data found no significant difference in its renal composite endpoint. Its limited follow-up must be acknowledged, but the results do not demonstrate renoprotection.
A later systematic review and meta-analysis pooled heterogeneous diabetic-complication studies and identified an overall decrease in urinary albumin excretion in some analyses. Such pooled findings should be read alongside the negative larger randomized trials rather than used to override them. Varying study quality, baseline therapy, intervention schedules and endpoints complicate comparison. Albuminuria improvement in selected studies is also not equivalent to demonstrated preservation of long-term kidney function.
| Study | Population / design | Primary evidence | Interpretation |
|---|---|---|---|
| Di.N.A.S. (2002) | 223 patients; randomized dose-ranging study | Reported a reduction in albuminuria at some doses | Positive early signal; does not establish hard renal benefit |
| Sun-MICRO (2011) | 1,056 with type 2 diabetes and microalbuminuria | Primary albuminuria response 16.5% vs 18.4% (sulodexide vs placebo) | No significant evidence of albuminuria benefit under trial conditions |
| Sun-MACRO (2012) | 1,248 with overt type 2 diabetic nephropathy; stopped early | Composite renal endpoint 26 vs 30 events (sulodexide vs placebo) | No significant renal benefit demonstrated |
| Systematic review (2021) | Mixed studies of diabetes-related complications | Pooled evidence suggested lower albumin excretion | Heterogeneity and negative large trials remain important |
Heparin and related anticoagulants have separate established uses in specific clinical settings, but they should not be treated as equivalent to strategies intended to reconstruct a renal glycocalyx. Clinical endpoints, bleeding risk, regulatory indications and background standard-of-care therapies must be considered separately for each intervention. This is a scientific evidence review, not a treatment recommendation.
7. Translational Challenges and Conflicting Evidence
7.1 Mechanistic ambiguity
A shift in circulating GAG fragments, permeability or UACR can arise from changes in synthesis, shedding, clearance, hemodynamics or tissue injury. Calling all such changes “glycocalyx recovery” oversimplifies the biology. Direct structural evidence and selective perturbation are needed to attribute a response to a particular GAG pathway.
7.2 Heterogeneous materials and exposure
Heparin, HS, HA and sulodexide vary in chain length, sulfation distribution, tissue source and protein affinities. Equal mass concentrations are not equal molar concentrations of chains or binding motifs. In vivo exposure differs from concentrations used in cell culture because of route, clearance and plasma-protein interactions.
7.3 Reconciling negative and positive findings
Preclinical models can demonstrate an effect under constrained conditions yet fail to predict additive benefit on top of optimized human care. Genetic deletion of GBM HS challenges simplistic charge-barrier explanations, while observations about endothelial glycocalyx may still be biologically meaningful. Likewise, positive pooled albuminuria results and negative large sulodexide trials are not mutually exclusive descriptions of the same populations or outcomes. The appropriate conclusion is that clinical efficacy and causal mechanisms remain intervention- and context-specific.
Specify the tissue compartment; analytically characterize the GAG; separate structural and functional endpoints; include relevant background therapy and controls; predefine endpoints; and report null findings with the same precision as positive effects.
8. Future Directions in Cardiovascular and Renal GAG Research
First, compartment-resolved analysis will help distinguish luminal endothelial surface remodeling from GBM or interstitial HS changes. Better spatial imaging and disaccharide-level mass spectrometry could identify whether changes involve chain abundance, molecular size or sulfation position rather than a generic loss of negative charge.
Second, clinically relevant microvascular systems should integrate physiological flow, podocytes, endothelial cells and extracellular matrix. Such models could test how diabetes-associated injury evolves across the whole filtration interface and separate direct barrier effects from immune or hemodynamic influences.
Third, targeted studies of complement regulation, including HS-dependent recruitment of factor H, may clarify roles of GAGs beyond passive permeability. These pathways deserve experiments that directly measure complement deposition and activity rather than inferring protection from surface staining alone.
Finally, clinical research needs transparent reporting of GAG composition, validated target engagement, prespecified outcomes and sufficient follow-up to assess sustained kidney or cardiovascular benefit. Biomarker improvements can guide hypothesis generation but should be confirmed against patient-important outcomes. Sulodexide and glycosaminoglycan research remains a useful example of why compelling biological rationale must be tested against rigorous human evidence.
Collectively, cardiovascular and renal GAG biology is best understood as a network of structural, signaling and immunoregulatory functions. Progress will depend not on assigning a single protective role to all negatively charged polysaccharides, but on matching distinct molecular structures to specific tissue compartments and rigorously validated effects.
References
- Suh JH, Miner JH. The glomerular basement membrane as a barrier to albumin. Nat Rev Nephrol. 2013;9(8):470–477. doi:10.1038/nrneph.2013.109.
- Harvey SJ, et al. Glomerular filtration is normal in the absence of both agrin and perlecan-heparan sulfate from the glomerular basement membrane. Nephrol Dial Transplant. 2009. PubMed record.
- Glomerular basement membrane heparan sulfate in health and disease: a regulator of local complement activation. Matrix Biol. 2016. PubMed record.
- Gambaro G, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002. PubMed record.
- Lewis EJ, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011. PubMed record.
- Packham DK, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012. PubMed record.
- Sulodexide for diabetic-induced disabilities: a systematic review and meta-analysis. Adv Ther. 2021. Full text.
- Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic? Am J Physiol Renal Physiol. 2017. Full text.